Spero Therapeutics (SPRO)

Executive Summary

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multidrug-resistant bacterial infections. Its lead asset, tebipenem HBr (oral carbapenem), recently achieved positive pivotal Phase 3 results in complicated urinary tract infections (cUTI) and acute pyelonephritis, demonstrating non-inferiority to intravenous ertapenem. This oral antibiotic addresses a significant unmet need, potentially reducing hospital stays and IV line use. The company is preparing an NDA submission for tebipenem, with a decision expected in the second half of 2026. Beyond tebipenem, Spero's pipeline includes SPR720 (for pulmonary nontuberculous mycobacterial disease), which halted Phase 2 enrollment due to efficacy signals but may be re-evaluated, and SPR206 (a novel polymyxin) in Phase 1. The company's valuation of ~$143 million reflects the high-risk high-reward nature of antibiotic development. With a strong Phase 3 result and a focused strategy, Spero is positioned to become a key player in the oral antibiotic space, pending regulatory approval and successful commercialization.

Upcoming Catalysts (preview)

• H2 2026FDA decision on tebipenem HBr for cUTI80% success
• H2 2026Potential partnership or licensing deal for tebipenem commercialization60% success
• Q4 2026Pipeline update or strategic refocus on SPR720 or SPR20650% success